FemiPro: A Structured Review
- Form
- capsule
- Price range
- ~$49–$79 per bottle depending on bundle size (no single-bottle option; smallest package is 2 bottles)
- Made in
- United States
- Marketed for
- FemiPro is presented as a dietary supplement for women's urinary and urogenital wellness, with stated focus areas of bladder control support, microbiome balance, and urinary system health.
- Main point of attention
- The active ingredients are grouped inside proprietary blends whose individual doses are not disclosed. As a result, it cannot be verified from the label whether any individual ingredient is present within the dose range studied in the literature for the intended effects.
Composition
| Ingredient | Dose in this product | Typical studied dose | Match |
|---|---|---|---|
| Mimosa pudica | — (in UTI Herbal Blend) | Not established | — |
| Cranberry extract | — (in UTI Herbal Blend) | 36–72 mg/day | — |
| Bearberry (uva-ursi) | — (in UTI Herbal Blend) | 400–840 mg/day | — |
| Berberine | — (in UTI Herbal Blend) | 900–1500 mg/day | — |
| Lactobacillus probiotic blend | — (in Probiotic Blend) | Not established | — |
UTI Herbal Blend + Probiotic Blend — UTI Herbal Blend 350 mg; Probiotic Blend 50 mg (individual doses and CFU counts not disclosed)
Indication of use
FemiPro is presented as a dietary supplement for women's urinary and urogenital wellness, with stated focus areas of bladder control support, microbiome balance, and urinary system health. Its ingredients are drawn from categories associated with urinary and urogenital health: cranberry, bearberry, and Lactobacillus species. The label also carries the marketing line "clinically researched ingredients," which cannot be verified for this formulation because the relevant doses are undisclosed.
Ingredient evidence
Mimosa pudica has a long history of use in traditional medicine systems for diverse indications (diarrhea, wounds, parasites, anxiety). Published human evidence is extremely limited and consists primarily of small uncontrolled reports; no randomized controlled trials of Mimosa pudica for urinary tract infection, bladder control, or urogenital microbiome are available in the peer-reviewed literature as of the review date. Most pharmacological claims rest on in-vitro and rodent studies.
View key studies
-
No randomized controlled trials of Mimosa pudica for urinary or urogenital indications were located.
Available human literature addresses unrelated indications (e.g. wound healing, parasitology case series) and is generally low-quality.
A 2023 Cochrane systematic review (Williams et al., CD001321.pub6) found that cranberry products reduce the risk of symptomatic, culture-verified UTI in women with recurrent UTIs, in children, and in people susceptible to UTIs after interventions; the review reports no clear benefit in elderly institutionalised people, pregnant women, or adults with neurogenic bladder. The literature most commonly associates clinical benefit with PAC-standardized preparations delivering at least ~36 mg PAC per day. Evidence is heterogeneous: efficacy depends on subpopulation, product form, and PAC dose, and unstandardized cranberry juice has not been shown to be effective in many trials.
View key studies
-
Williams G, Stothart CI, Hahn D, Stephens JH, Craig JC, Hodson EM. Cranberries for preventing urinary tract infections. Cochrane Database Syst Rev. 2023;4(4):CD001321.
PMID: 37068952
Updated Cochrane review (50 studies, ~8,857 participants). Cranberry products reduced the risk of symptomatic, culture-verified UTI in women with recurrent UTIs, in children, and in people susceptible to UTI after interventions; no clear benefit in elderly institutionalised people, pregnant women, or adults with neurogenic bladder.
Uva-ursi has long-standing traditional use for symptomatic, uncomplicated urinary tract infection in adult women, and is the subject of European Medicines Agency herbal monographs (traditional-use registration). The published modern clinical evidence base is limited and heterogeneous; the most relevant contemporary trial is the ATAFUTI randomised double-blind trial in UK primary care, which evaluated uva-ursi (with or without ibuprofen) for symptom relief in women with suspected uncomplicated UTI and did not demonstrate a clear reduction in antibiotic use or symptom duration. Routine long-term use is discouraged in standard herbal pharmacopeias because of concern about hydroquinone exposure.
View key studies
-
Moore M, Trill J, Simpson C, et al. Uva-ursi extract and ibuprofen as alternative treatments for uncomplicated urinary tract infection in women (ATAFUTI): a factorial randomized trial. Clin Microbiol Infect. 2019;25(8):973–980.
PMID: 30685500
Factorial RCT in UK primary care (n=382) in women with suspected uncomplicated UTI. Uva-ursi (three times daily for up to a week) did not significantly reduce symptom severity or antibiotic use compared with placebo.
Multiple randomized controlled trials and meta-analyses support efficacy for glycemic control in type 2 diabetes and metabolic syndrome at doses around 1,500 mg/day. Effects on HbA1c are comparable to first-line oral hypoglycemics in some studies.
View key studies
-
Yin J, Xing H, Ye J. Efficacy of berberine in patients with type 2 diabetes mellitus. Metabolism. 2008;57(5):712-7.
PMID: 18442638
RCT comparing berberine 500mg TID to metformin 500mg TID in 36 newly diagnosed T2D patients. HbA1c reduction was comparable between groups (~2% absolute reduction).
-
Lan J, Zhao Y, Dong F, et al. Meta-analysis of the effect and safety of berberine in the treatment of type 2 diabetes mellitus, hyperlipemia and hypertension. J Ethnopharmacol. 2015;161:69-81.
PMID: 25498346
Meta-analysis of 27 RCTs (2,569 participants). Berberine showed significant reduction in fasting blood glucose, HbA1c, total cholesterol, and triglycerides.
Probiotic evidence in urinary and urogenital health is strain- and route-specific: results from one strain or route of administration do not generalize to other strains or to oral multi-strain blends. No trial of this oral multi-strain blend as formulated has been identified, and the per-strain CFU is not disclosed on the label, so the blend cannot be matched to published per-strain dose ranges. Oral probiotic evidence for urinary tract infection prevention more broadly is heterogeneous and less consistent than intravaginal strain-specific evidence.
Components of the UTI Herbal Blend + Probiotic Blend are not individually disclosed and therefore not evaluated.
Safety profile
The label advises not to exceed the recommended dose and states that pregnant or nursing women, children under 18, and individuals with a known medical condition should consult a physician before use. Published literature notes that bearberry (uva-ursi) contains hydroquinone precursors and is generally described as appropriate only for short-term use, with caution in pregnancy and in renal conditions, and that berberine has documented interactions with several medications, including effects on drug-metabolizing enzymes and on agents used for blood sugar. Because individual doses within the blends are not disclosed, the clinical significance of these considerations for this specific product cannot be assessed from the label. As with any multi-ingredient botanical-plus-probiotic supplement, individuals taking prescription medications, those who are pregnant or lactating, and those managing chronic conditions are the population for whom professional consultation is most relevant.
Factual observations
- The product's ingredients match its stated category: cranberry, bearberry, and Lactobacillus strains are genuinely associated with urinary and urogenital health.
- The cranberry extract is standardized to 30% proanthocyanidin — a meaningful specification that many cranberry products omit.
- Lactobacillus crispatus is included, the species with the most published support in female urogenital health.
- The product discloses cGMP certification and FDA-registered facility manufacturing, and itemizes its inactive ingredients.
- The active ingredients are grouped inside proprietary blends whose individual doses are not disclosed. As a result, it cannot be verified from the label whether any individual ingredient is present within the dose range studied in the literature for the intended effects.
- Mimosa pudica has no published human urinary-health trials; its inclusion rests on traditional and in-vitro grounds.
- The label's "clinically researched ingredients" statement cannot be verified for this formulation, because the relevant doses are undisclosed.
Pricing and availability are set by the manufacturer and may change after the last review date. NaturaPeak does not sell this product directly. Any purchase link shown may be an affiliate link, as described below.